SG11201606106SA - Specific biomarker set for non-invasive diagnosis of liver cancer - Google Patents
Specific biomarker set for non-invasive diagnosis of liver cancerInfo
- Publication number
- SG11201606106SA SG11201606106SA SG11201606106SA SG11201606106SA SG11201606106SA SG 11201606106S A SG11201606106S A SG 11201606106SA SG 11201606106S A SG11201606106S A SG 11201606106SA SG 11201606106S A SG11201606106S A SG 11201606106SA SG 11201606106S A SG11201606106S A SG 11201606106SA
- Authority
- SG
- Singapore
- Prior art keywords
- liver cancer
- specific biomarker
- invasive diagnosis
- biomarker set
- invasive
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/321,870 US9885718B2 (en) | 2014-07-02 | 2014-07-02 | Specific biomarker set for non-invasive diagnosis of liver cancer |
| US14/321,867 US9506925B2 (en) | 2014-07-02 | 2014-07-02 | Specific biomarker set for non-invasive diagnosis of liver cancer |
| PCT/US2014/049038 WO2016003479A1 (en) | 2014-07-02 | 2014-07-31 | Specific biomarker set for non-invasive diagnosis of liver cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201606106SA true SG11201606106SA (en) | 2016-08-30 |
Family
ID=55019816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201606106SA SG11201606106SA (en) | 2014-07-02 | 2014-07-31 | Specific biomarker set for non-invasive diagnosis of liver cancer |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP3164711A4 (en) |
| JP (2) | JP2017520763A (en) |
| KR (1) | KR102086788B1 (en) |
| CN (2) | CN105319362B (en) |
| AU (2) | AU2014399919B2 (en) |
| CA (1) | CA2939912C (en) |
| HK (2) | HK1248803A1 (en) |
| MY (2) | MY179845A (en) |
| NZ (1) | NZ722492A (en) |
| SG (1) | SG11201606106SA (en) |
| TW (1) | TWI700493B (en) |
| UY (1) | UY36200A (en) |
| WO (1) | WO2016003479A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106383231B (en) * | 2016-09-02 | 2020-03-17 | 四川大学 | Marker combination for diagnosing liver cancer and application thereof |
| KR102175265B1 (en) | 2019-03-13 | 2020-11-06 | 충남대학교산학협력단 | Biomarker composition comprising TXNDC7 for diagnosis or predicting prognosis of hepatocellular carcinoma |
| CN110646615B (en) * | 2019-08-27 | 2021-07-13 | 南方医科大学 | Biological marker and treatment target of hepatic fibrosis and application thereof |
| WO2023282916A1 (en) | 2021-07-09 | 2023-01-12 | Guardant Health, Inc. | Methods of detecting genomic rearrangements using cell free nucleic acids |
| CN113502328A (en) * | 2021-05-27 | 2021-10-15 | 深圳市人民医院 | Application of reagent for detecting expression level of marker in sample in preparation of kit for detecting or diagnosing breast cancer |
| CN113777295B (en) * | 2021-09-15 | 2024-03-19 | 江南大学 | High-sensitivity quantum dot probe for detecting tumor marker PD-L1, preparation method and application |
| CN113956344A (en) * | 2021-10-14 | 2022-01-21 | 江南大学 | Novel FGF analogue for treating liver cancer and application thereof |
| CN114113611B (en) * | 2021-12-13 | 2023-07-14 | 郑州大学 | Biomarker for liver cancer diagnosis and detection kit |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6449562B1 (en) * | 1996-10-10 | 2002-09-10 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and method |
| US6893844B1 (en) * | 1998-09-22 | 2005-05-17 | Long Yu | DNA encoding a new human hepatoma derived growth factor and producing method thereof |
| US7387881B2 (en) * | 2001-09-19 | 2008-06-17 | The Regents Of The University Of Michigan | Detection and treatment of cancers of the liver |
| WO2003058201A2 (en) * | 2001-12-31 | 2003-07-17 | Quark Biotech, Inc. | Methods for identifying marker genes for cancer |
| GB0228900D0 (en) | 2002-12-11 | 2003-01-15 | Ml Lab Plc | Cancer Immunotherapy |
| JP3960614B2 (en) * | 2003-08-31 | 2007-08-15 | 株式会社イムノディア | Anti-peptide antibody measurement method and vaccine candidate selection method for peptide vaccine |
| GB0406215D0 (en) * | 2004-03-19 | 2004-04-21 | Procure Therapeutics Ltd | Prostate stem cell |
| EP1761648A1 (en) * | 2004-06-18 | 2007-03-14 | Roche Diagnostics GmbH | Use of protein pdx1 as a marker for breast cancer |
| JP5211315B2 (en) | 2006-07-25 | 2013-06-12 | 国立大学法人愛媛大学 | Tumor marker, tumor diagnostic kit, and method for measuring tumor marker |
| KR20100040964A (en) * | 2007-08-10 | 2010-04-21 | 가꼬우호우징 효고 이카다이가쿠 | Novel liver cancer marker |
| US8512963B2 (en) * | 2009-11-25 | 2013-08-20 | The Johns Hopkins University | Detection and quantitation of full-length thioredoxin (TRX) and truncated thioredoxin (TRX 80) in complex samples |
| US9523680B2 (en) * | 2010-06-30 | 2016-12-20 | Ambergen, Inc. | Global Proteomic screening of random bead arrays using mass spectrometry imaging |
| JP5493130B2 (en) | 2010-08-25 | 2014-05-14 | 国立大学法人山口大学 | Autoantibody detection method |
| US20140141986A1 (en) * | 2011-02-22 | 2014-05-22 | David Spetzler | Circulating biomarkers |
| WO2013049704A2 (en) * | 2011-09-28 | 2013-04-04 | Armune Biosciences, Inc. | Method and system of particle-phage epitope complex |
-
2014
- 2014-07-31 KR KR1020167032783A patent/KR102086788B1/en active IP Right Grant
- 2014-07-31 MY MYPI2017001446A patent/MY179845A/en unknown
- 2014-07-31 MY MYPI2016002278A patent/MY195045A/en unknown
- 2014-07-31 SG SG11201606106SA patent/SG11201606106SA/en unknown
- 2014-07-31 CA CA2939912A patent/CA2939912C/en active Active
- 2014-07-31 EP EP14896556.9A patent/EP3164711A4/en not_active Withdrawn
- 2014-07-31 TW TW103126171A patent/TWI700493B/en active
- 2014-07-31 AU AU2014399919A patent/AU2014399919B2/en active Active
- 2014-07-31 WO PCT/US2014/049038 patent/WO2016003479A1/en active Application Filing
- 2014-07-31 NZ NZ72249214A patent/NZ722492A/en unknown
- 2014-07-31 JP JP2016571689A patent/JP2017520763A/en active Pending
-
2015
- 2015-07-01 CN CN201510379493.9A patent/CN105319362B/en active Active
- 2015-07-01 UY UY0001036200A patent/UY36200A/en unknown
- 2015-07-01 CN CN201710545890.8A patent/CN107478842B/en active Active
-
2016
- 2016-06-13 HK HK18107745.3A patent/HK1248803A1/en unknown
- 2016-06-13 HK HK16106781.2A patent/HK1224370A1/en unknown
-
2017
- 2017-09-21 AU AU2017232129A patent/AU2017232129B2/en not_active Ceased
-
2020
- 2020-06-22 JP JP2020106731A patent/JP2020160082A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017520763A (en) | 2017-07-27 |
| AU2017232129B2 (en) | 2018-10-25 |
| AU2017232129A1 (en) | 2017-10-12 |
| CN107478842A (en) | 2017-12-15 |
| EP3164711A1 (en) | 2017-05-10 |
| KR102086788B1 (en) | 2020-03-09 |
| CA2939912A1 (en) | 2016-01-07 |
| TW201602579A (en) | 2016-01-16 |
| CN107478842B (en) | 2020-10-16 |
| HK1224370A1 (en) | 2017-08-18 |
| MY179845A (en) | 2020-11-18 |
| KR20170021234A (en) | 2017-02-27 |
| AU2014399919A1 (en) | 2016-08-11 |
| CA2939912C (en) | 2019-04-16 |
| AU2014399919B2 (en) | 2019-10-24 |
| EP3164711A4 (en) | 2018-05-23 |
| WO2016003479A1 (en) | 2016-01-07 |
| CN105319362A (en) | 2016-02-10 |
| UY36200A (en) | 2016-01-29 |
| CN105319362B (en) | 2018-07-13 |
| MY195045A (en) | 2023-01-04 |
| NZ722492A (en) | 2019-09-27 |
| JP2020160082A (en) | 2020-10-01 |
| HK1248803A1 (en) | 2018-10-19 |
| TWI700493B (en) | 2020-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272572B (en) | Antibody compositions for tumor treatment | |
| SG11201700944RA (en) | Microrna biomarker for the diagnosis of gastric cancer | |
| ZA201701753B (en) | Biomarkers for assessing breast cancer | |
| PL3122358T3 (en) | Combinations of fgfr- and cmet-inhibitors for the treatment of cancer | |
| HK1224370A1 (en) | Specific biomarker set for non-invasive diagnosis of liver cancer | |
| IL285077A (en) | Compounds for treatment of cancer | |
| GB201420859D0 (en) | Tumour analysis | |
| IL251376A0 (en) | Methods for assessing risk of developing breast cancer | |
| EP3227686A4 (en) | Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer | |
| HK1253082A1 (en) | Method of diagnosis of breast cancer | |
| EP3204008A4 (en) | Use of biomarkers for predicting clinical sensitivity to cancer treatment | |
| SG10201913528PA (en) | Methods of diagnosing cancer | |
| SG11201701076TA (en) | Diagnosis of cancer | |
| PL3152576T3 (en) | Use of tm9sf4 as a biomarker for tumor associated exosomes | |
| EP3189332A4 (en) | Biomarkers for detection of breast cancer | |
| IL248126A0 (en) | Combination of cancer therapeutics | |
| GB201410118D0 (en) | Early diagnosis of leptospire | |
| GB201407837D0 (en) | Methods of cancer therapy | |
| ZA201704589B (en) | Compounds for the treatment of cancer | |
| GB201414362D0 (en) | Biomarkers for early diagnosis of ovarian cancer | |
| GB201405286D0 (en) | Cancer diagnostic | |
| AU2014903898A0 (en) | Methods for assessing the risk of developing breast cancer | |
| GB201400387D0 (en) | Diagnostic for gastric cancer | |
| GB201411489D0 (en) | Kit for diagnosis of foetal distress | |
| AU2014901825A0 (en) | Biomarker of Disease |